Presentations

Corporate Presentation and Research Reports

Corporate Presentation and Research Reports

Corporate Presentation

MediciNova Corporate Presentation – August 24, 2021

Zacks Research Reports

MNOV: Animal Trials Commence Testing MN-166 as an MCM – August 16, 2021

MNOV: Positive Results for MN-166 in Phase 2 AUD Trial – June 22, 2021

MNOV: Phase 3 ALS Trial Ongoing – May 28, 2021

MNOV: Milestone Payments from Legacy Gene Therapy Assets – April 26, 2021

MNOV: BARDA Contract to Support Development of MN-166 in ARDS – March 15, 2021

MNOV: $20M Investment to Fund Multiple Programs – January 25, 2021

MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID- 19 Patients – July 2, 2020

MNOV: Multiple ‘Shots on Goal’ Provide Substantial Potential Upside – May 1, 2020

MNOV: MN-166 to be Developed as a Treatment for Severe Pneumonia and Acute Respiratory Distress Syndrome – March 12, 2020

MNOV: Multiple Trials of MN-166 Ongoing; Recent Price Move Creates Buying Opportunity – February 25, 2020

MNOV: Phase 3 Trial Initiated for MN-166 in ALS – October 30, 2019

MNOV: Abstract on MN-166 to be Presented at ALS/MND International Symposium – August 14, 2019